Press Releases

UPLIZNA™ is the first and only B cell depleter approved for the treatment of NMOSD in adults who are anti-aquaporin-4 (AQP4) antibody positive GAITHERSBURG, Md. , June 11, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE) today announced that the U.S. Food and Drug Administration (FDA) has approved

GAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq: VIE ), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at

GAITHERSBURG, Md. , May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at

GAITHERSBURG, Md. , May 26, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced that it intends to offer and sell, subject to market and other conditions, 3,000,000

Company to host investor conference call and webcast today at 5:00 pm ET GAITHERSBURG, Md. , May 13, 2020 (GLOBE NEWSWIRE) -- Viela Bio  (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today reported financial results and

-Safety profile comparable to placebo control- -Potent depletion of plasmacytoid dendritic cells in peripheral blood and skin biopsies- -Dose-dependent improvements in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scores- GAITHERSBURG, Md.

GAITHERSBURG, Md. , May 06, 2020 (GLOBE NEWSWIRE) -- Viela Bio  (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today announced it will host a webcast and conference call on Wednesday, May 13, 2020 at 5:00 p.m.

GAITHERSBURG, Md. , April 30, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the election of Rachelle Jacques to its Board of Directors.

Company to host investor conference call and webcast today at 5:00 pm ET GAITHERSBURG, Md. , March 25, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today reported financial results and

GAITHERSBURG, Md. , March 18, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today announced it will host a webcast and conference call on Wednesday, March 25, 2020 at 5:00 p.m.